Despite recent market turbulence, Oppenheimer Asset Management expressed continued optimism about equities in a statement ...

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...

Joshua Oppenheimer made his name directing two disturbing documentaries, The Act of Killing (2012) and The Look of Silence (2014), that dealt with the aftermath of the brutal anti-communist massacres ...

Oppenheimer expects S&P 500 to bounce back a little in April. The investment firm warns the bounce could prove short lived.

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

Oppenheimer analysts called the M&A rebound “delayed or cancelled." Oppenheimer also downgraded its ratings to "perform" from ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...

Yet, MAD still dominates countries’ nuclear thinking. Opinion: Our nuclear weapons are much more powerful than Oppenheimer's atomic bomb At a time of profound global changes and instability ...

Oppenheimer analyst Steven Lichtman maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of $105.00. The ...

Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...